Xvivo Perfusion stock
XVIVO.STSTOXvivo Perfusion AB (publ), HealthcareISIN SE0004840718
50Score 50 out of 100, Neutral
Price and trend
42 / 100
Price history
+19% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 17% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 34% below its 52-week high. Largest decline in 14 years: 71% (September 2021 to October 2022).
Chart figures for advanced users
- SMA 50$22.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.28
- The lowest closing price of the last twelve months.
- Resistance$30.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Xvivo Perfusion AB (publ) belongs to the Medical (Devices) industry (Sweden) and, with a market value of $640.54M, is number 72 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $81.44M (down 1.2% year on year) and earnings of $2.52M (down 85.4%).
- For fiscal 2026, analysts expect on average revenue of $99.12M (up 21.7%) and adjusted earnings per share of $0.37 (up 278.6%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 381 of 702 in Healthcare, median 53.
- The P/E is 49.6 (Medical (Devices) median 29.1, own median of recent years 98.4).
- Our model puts fair value at $6.20, with the price 228% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 35.2% a year since 2020, Medical (Devices) median 13.8%.Growth 70
- Analysts expect strong earnings growthUp 36.9% a year through 2028 (estimates from 4 analysts).Growth 70
- More cash than debtCash $31.41M, financial debt $12.09M.Stability 62
Weaknesses
- Above fair valuePrice 228% above the fair value of $6.20.Valuation 26
- Interest barely coveredOperating profit covers interest only 1.9 times.Stability 62
- DilutionShare count up 16% since 2020.Capital allocation 27
Its standout strength is growth, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $4.43 and expensive above $10.33 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $0.48 (cash-flow model) and $11.92 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $6.12, at 6.2% it would be $6.32.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17.8% on the twelve months before. Revenue has grown strongly since 2012, at around 36% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 66%, operating 11%, net 3%. Last 12 months: net 13%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 28 Jan 2027in 76 days
- Last reported
- 22 Oct 2026EPS reported $0.14 (expected $0.06)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 9.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.37+7.2%
- Revenue
- $99.12M−0.3%
- Earnings per share
- $0.53−9.8%
- Revenue
- $120.42M−3.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −17.7%No numerical outlook; organ recovery volumes remained below expectations for another quarter, but management believes the momentum will continue.
“The development continues to be explained mainly by lower organ recovery volumes, while FlowHawk delivers another strong quarter.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 14 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Xvivo Perfusion
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Beta BionicsBBNX $742.78M46
- Cytek BiosciencesCTKB $721.93M46
- Synektik Spólka AkcyjnaSNT.WA $718.95M78
- Senseonics HoldingsSENS $659.99M44
- Pacific Biosciences of CaliforniaPACB $612.34M35
- Sight SciencesSGHT $610.81M48
- MedistimMEDI.OL $604.15M81
- Tactile Systems TechnologyTCMD $600.81M68
ETFs that hold Xvivo Perfusion
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.07% | 0.23% | €321.86M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.05% | 0.40% | €1.5B |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.03% | 0.30% | €3.45B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.01% | 0.30% | €813.64M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 11 Nov 2026, previously Weak
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.